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INTRODUCTION
Colon cancer is one of the most common malignancies in
many regions of the world (1). Also in Japan, the numbers
of cases of colorectal cancer are increasing with the spread of
Western dietary habits (2). The idea that this cancer might
be a candidate for chemoprevention stems from epidemio-
logical evidence that some factors in the diet may play impor-
tant roles in its development, whereas others may reduce the
risk (3, 4). In animal studies, repeated treatment with a car-
cinogen, 1,2-dimethylhydrazine (DMH), produces colon
tumors in rodents (5, 6). Colon carcinogenesis models using
DMH or the related azoxymethane, with putative preneo-
plastic aberrant crypt foci (ACF) as end-point marker lesions,
have been used to assess the influence of modulatory factors
(7, 8).
ACF are readily discernible morphological changes with-
in the colonic mucosa of  rodents that may contribute to the
stepwise progression to colon cancer (9-11). Pretlow and co-
workers (12) showed that these lesions are also present in the
colonic mucosa of patients with colon cancers and suggested
that they are putative precursor lesions from which adenomas
and carcinomas may develop. The formation and growth of
ACF are associated with induction of colon tumors in rats
and are influenced by exposure to chemopreventive agents
(13, 14). Natural compounds that inhibit ACF induced by
colon carcinogens have proved to be protective against colon
cancer in rodents (13, 15). 
Ginseng is believed to have been used in medicinal prepa-
rations for about 2000 yr in Oriental countries. Several
pharmacological activities have been reported for ginseng
extracts or ginseng dammarance saponins (16-19). Each
type of ginseng can be ingested in various forms, for exam-
ple, as fresh slices, juice, extract (tincture or boiled extract),
powder, tea, tablet, or capsule (20). Preventive effects of
ginseng against cancer development have been observed for
many of these, including fresh ginseng extract, white gin-
seng extract, white ginseng powder, and red ginseng prod-
ucts, but not fresh ginseng slices, fresh ginseng juice, and
white ginseng tea (20).
Antitumor effects of ginseng have also been supported by
animal studies (21-26). For example, a medium-term (8)
model system revealed anti-carcinogenic activity of ginseng
regarding pulmonary adenoma induction by benzo[a]pyrene
in newborn mice (27). In humans, anticancer influence of
ginseng has been documented (20, 28). Although ginseng
was found in one study to have a non-organ-specific preven-
tive effect against cancer (29), there are weak negative asso-
ciations between ginseng intake and cancers of the female
breast, uterine cervix, urinary bladder, and thyroid gland. It
is also associated with decreased odds ratios for cancers of
the lip, oral cavity, pharynx, esophagus, stomach, colorec-
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Inhibition by Ginseng of Colon Carcinogenesis in Rats
The inhibitory effects of ginseng on the development of 1,2-dimethylhydrazine
(DMH)-induced aberrant crypt foci (ACF) in the colon were investigated in rats.
Male, 6-week-old rats were injected with DMH once a week for 4 weeks. Rats in
Groups 1 and 2 were fed diets containing red and white ginseng, rerspectively,
at a dose of 1% for 5 weeks, starting one week before the first treatment of
DMH. Animals in Groups 3 and 4 received red or white ginseng for 8 weeks
starting after DMH treatment. Group 5 served as a carcinogen control group.
Numbers of ACF with at least four crypts were significantly reduced in the colon
of Group 2 treated with red ginseng combined with DMH. Moreover, rats were
injected with DMH 4 times at one-week intervals. They were also fed diets con-
taining 1% red or white ginseng or the control diet throughout 30 days of the
experiment. Treatment with red ginseng resulted in a significant decrease of 5-
bromo-2′ -deoxyuridine labeling indices in colonic crypts comprising ACF. These
findings suggest that dietary administration of red ginseng in combination with
DMH suppresses colon carcinogenesis in rats, and the inhibition may be associ-
ated, in part, with inhibition of cell proliferation, acting on ACF in the colonic
mucosa. 
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tum, liver, pancreas, larynx, lung, and ovary (20). 
In the present study, inhibitory effects of ginseng in a DMH-
induced colon carcinogenesis model in rats were assessed,
with attention concentrated on quantitative values for pre-
neoplastic ACF and cellular proliferative status in terms of
5-bromo-2′ -deoxyuridine (BrdU) labeling (30).
MATERIALS AND METHODS
Animals
A total of 125 male five-week-old F-344 rats (Charles River,
Hino, Shiga, Japan) were housed five per plastic cage with
wood chips for bedding in an animal room under standard
conditions. Body weight and food intake were measured
weekly during the experiment. Diet and water were avail-
able ad libitum.
Chemicals
DMH was purchased from Wako Pure Chemical Indus-
tries (Osaka, Japan). White ginseng and red ginseng pow-
ders were obtained from Wakunaga Pharmaceutical Co. Ltd.
(Hiroshima, Japan), and each was administered at a concen-
tration of 1% in CE-2 basal diet (Clea Japan, Osaka, Japan).
Ginseng powders were from the roots of Panax ginseng C.A.
Meyer cultivated in China.
Experimental protocols
In Experiment 1, 65 five-week-old rats were divided into
eight groups. Animals in Groups 1-5 (10 rats in each group)
were given DMH (20 mg/kg body weight, subcutaneous)
once a week for 4 weeks. Rats in Groups 6-8 (5 rats each
group) were subcutaneously injected with 0.9% saline (vehi-
cle) at the same time. Groups 1 and 2 also received diets
containing red and white ginseng, respectively, for 5 weeks,
starting one week before the first DMH or saline treatment.
Groups 3 and 4 were similarly fed diets containing red and
white ginseng after DMH treatment (Weeks 5-12 ). Group
5 served as a carcinogen-treated control. The animals of
Groups 6 and 7 were fed a diet containing red and white
ginseng without DMH, and Group 8 (the vehicle control)
received the basal diet alone throughout the experiment
period.
In Experiment 2, 60 five-week-old rats were divided into
6 groups of 10 rats each and injected with DMH at 20 mg/kg
body wt, sc (Groups 1-3) or saline alone (Groups 4-6) 4 times
at one-week intervals (Weeks 1-4). The rats were fed diets
containing red ginseng (Groups 1 and 4) and white ginseng
(Groups 2 and 5) or the control diet (Groups 3 and 6), respec-
tively, for 30 days, starting one week before the first DMH
or saline treatment.
Animals were sacrificed under ether anesthesia at week 12
(Experiment 1) and the second day after the last injection of
DMH (Experiment 2), respectively. All 60 rats in Experiment
2 received a single injection of BrdU (Sigma Chemical, St.
Louis, MO; 100 mg/kg body wt, ip) one hour  before sacri-
fice. After the colon was stained with 0.2% methylene blue
as described previously (30), ACF were examined under a
stereomicroscope. After they were counted, the colons were
examined for BrdU immunohistochemistry, as described
earlier (31).
Statistical Analysis
Statistical analyses were completed with Stat-View soft-
ware on a Macintosh computer. The significance of differ-
ences between average values for groups was analyzed using
Cochran’ s two-tailed Student’ s t-test.
RESULTS
Experiment 1
All rats survived to the final sacrifice. The body weights
of animals given DMH and red or white ginseng were small-
er than those treated with DMH alone, and final average
body weights of rats in Groups 1-3 were significantly lower
than those in the control groups. Among the vehicle-treat-
ed animals, the relative liver weights in Group 7 were sig-
nificantly lower than those in Group 8. Food consumption
on a rat-per-cage basis was comparable among the groups.
Animals administered saline (vehicle) and fed the control
Total No. of ACF Treatment
Group
No.
No. of
rats 1 crypt 2 crypts 3 crypts ≥4 crypts
1 10 DMH+WG 282.1±58.5 97.7±34.9 89.3±21.7 55.1±15.0 37.9±24.8
2 10 DMH+RG 177.5±92.3* 56.2±28.2* 70.4±36.5 32.9±24.1* 18.2±10.0*
3 10 DMH→WG 222.7±45.4* 81.6±33.5 76.7±14.6 39.4±8.3** 25.0±11.2
4 10 DMH→RG 292.3±83.6 89.8±24.5 93.2±27.5 64.3±42.7 45.8±31.3
5 10 DMH 305.5±56.0 115.5±42.9 91.1±20.8 61.7±13.2 37.2±13.8
Table 1. Effects of Ginseng on DMH-Induced ACF Formation in the Colons of rats: Experiment 1
a,b
DMH,1,2-dimethylhydrazine; WG, white ginseng; RG, red ginseng; ACF, aberrant crypt foci. 
a: Values are means±SD; n: number of rats, 
b: Statistical
significance is as follows: *, p� 0.01; **, p� 0.001 vs. Group 5.
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and experimental diets containing red or white ginseng
lacked any ACF in the colon (data not shown). Table 1 sum-
marizes data for DMH-induced ACF in the colons of rats
fed the control and experimental diets (Groups 1-5). Admin-
istration of red or white ginseng in the diet (Groups 2 and
3) significantly suppressed the total number of ACF per
colon compared with the control diet (Group 5). Particular-
ly in animals fed red ginseng during initiation (Group 2),
there was a significant reduction in the number of large ACF
containing at least four crypts per focus, which have been
reported to be more likely to develop into tumors (14). Num-
bers of foci containing three crypts were also significantly
decreased by feeding white ginseng after DMH administra-
tion (Group 3). The distribution and frequency of ACF in
Groups 1-5 were predominantly observed in the distal colon.
Group 2 demonstrated a significantly lowered occurrence of
ACF in all regions of the colon.
Experiment 2
Exposure to red ginseng (Group 2) relative to the control
(Group 3) significantly reduced the formation of ACF (Table
2). Rats administered saline (Groups 4-6) had no ACF in the
colon (date not shown). Crypts containing ACF had more
BrdU-labeled cells than normal-appearing crypts. Crypts
containing ACF in animals fed red ginseng had fewer BrdU-
labeled cells than those of animals fed the basal diet. As shown
in Fig. 1, the BrdU labeling index was significantly suppressed
within ACF in the animals (Group 2) fed the diet with red
ginseng. The inhibition was evident along the length of the
colon.
DISCUSSION
The present study was undertaken to evaluate red or white
ginseng for potential inhibition of ACF formation in the
colon, putative preneoplastic lesions (10-12). The results
indicate that dietary red ginseng powder exposure during
the initiation phase exerts significant inhibition potential.
The colon tumor incidence in rats correlates best with num-
bers of large ACF (�4 crypts/focus), which are more likely
to persist, increase in size through multiplication (9, 11), and
develop into tumors (14). Large ACF are also linked with
colon cancer development from the viewpoint of dysplastic
change (10, 11), altered proliferative pattern (11), K-ras
mutations (32), and DNA adduct formation (33). There-
fore, the finding of significant reduction of large ACF (�4
crypts/focus) might point to an effect on tumor yield. Al-
though this requires confirmation in a long-term experi-
ment, the results provide support for human intervention
trials of red ginseng as a cancer-chemopreventive agent.
Ginseng has potent cancer-chemopreventive effects in
humans (20, 23, 24, 28). Epidemiological studies have shown
that the odds ratios of ginseng consumers are decreased with
all kinds of cancers in case-control studies (20, 28). Recent-
ly, a prospective study to evaluate the preventive effect of
ginseng against lung cancer in humans also revealed a reduced
risk with ginseng intake, adjusted for smoking, with no
cancer death among 24 red ginseng consumers (29). In the
present study, significant decrease of the number of large
ACF was not observed in animals given white ginseng pow-
der, although total colonic ACF were reduced (Experiment
1). Therefore, the present study indicated that white gin-
seng is not as effective as red ginseng at inhibiting DMH-
induction of ACF development in the rat colon.
Concerning the effects of red ginseng, Yun and co-workers
Total No. of ACF Treatment
Group
No.
No. of
rats 1 crypt 2 crypts 3 crypts ≥4 crypts
1 DMH+WG 10 111.0±22.9 101.4±23.1 8.2±4.4 0.3±0.5 0.1±0.3
2 DMH+RG 10 63.2±19.3* 56.7±16.3* 6.0±4.2* 0.6±0.7 0
3 DMH 10 169.6±80.2 149.5±75.2 13±5.5 0.5±0.7 0.1±0.3
Table 2. Effects of Ginseng on DMH-Induced ACF Formation in the Colons of Rats: Experiment 2
a,b
DMH,1,2-dimethylhydrazine; WG, white ginseng; RG, red ginseng; ACF, aberrant crypt foci. 
a: Values are means±SD; 
b: Statistical significance is as
follows; *, p� 0.01 vs. Group 3.
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Fig. 1. 5-Bromo-2’-deoxyuridine labeling indices in colonic mucos-
al crypts within aberrant crypt foci (ACF) in rats fed ginseng or
basal diet (Experiment 2)  , DMH+white ginseng (Group 1);
, DMH+red ginseng (Group 2);  , DMH (Group 3); *, p<0.05
vs. Group 3.
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(21) carried out extensive animal experiments to investigate
whether ginseng inhibited carcinogenesis. They reported
that oral administration of red ginseng extract inhibited the
incidence and the proliferation of lung tumours induced by
various chemical carcinogens in mice. It was considered that
the anticarcinogenic mechanism partly involved elevation of
natural killer cell activity (34, 35). Matsuda and colleagues
(36, 37) reported that red ginseng inhibited formation of
pulmonary metastases after infusion of tumor cells into rats
and that combined with mitomycin C showed a stronger
antitumor effect, with enhanced in vitro cytotoxicity, than
the same combination with white ginseng. Moreover, it has
been reported that the ability of red ginseng saponins to
inhibit lung metastasis of tumor cells in mice is related to
inhibition of adhesion and invasion of tumor cells and also
to antiangiogenesis (23). In terms of the effect of ginseng on
body weight of rats, Table 1 shows no toxic effect of red or
white ginseng in the control Groups 6 or 7 compared with
Group 8 in Experiments 1 and 2. However, a significant
decrease in body weight was noted in Groups 1-3 in Exper-
iment 1 and Group 2 in Experiment 2. The decrease in
body weight was seen only in groups treated with DMH
simultaneously with or before ginseng administration. A
possible synergistic effect of ginseng with DMH metabo-
lites could affect body weight; therefore, the body weight
loss in the present experiment could be a DMH- specific
phenomenon.
Ginseng is classified into three types depending on how
it is processed: fresh ginseng, white ginseng, and red ginseng.
White ginseng is four to six yr old and dried after peeling;
red ginseng is harvested when it is six yr old and then steamed
and dried. The major active components of ginseng are 20
(s)-protopanaxadiol and 20(s)-protopanaxatrial saponins. The
specific properties of saponin components of white and red
ginseng preparations have been reported (23, 38, 39). Con-
sidered to be the major active components (40), saponins
have been reported to have antimutagenic activity, inhibit
tumor angiogenesis and metastasis (23, 41), reduce growth
of several tumor cell lines (42) and human ovarian cancers
in nude mice (25, 26), and exert immunomodulating poten-
tial (43, 44). The chemical proporties and biological effects
of triterpenoid saponin components (ginsenosides) have been
widely studied (23, 39, 45, 46). Although red ginseng con-
tains other tumor growth-inhibitory substances (47), many
investigators have shown that ginsenosides suppress tumor
growth and inhibit tumor metastasis (23, 24, 48). Karikura
and associates (49, 50) described five and six decomposition
products of ginsenoside Rb1 and ginsenoside Rb2, respec-
tively, in the rat large intestine after oral administration. It
is not known, however, which component of red ginseng has
the most profound effect on cancer, and clearly studies focused
on this question are of high priority.
Modulation of cell proliferation in ACF and colon epithe-
lial cells has been proposed as a mechanism whereby agents
impact on colon cancer (51, 52). BrdU is a good parameter
for evaluating cell proliferation, because only S phase cells
are labeled, although care in its use is necessary, since BrdU
has been classified as a potential carcinogen (53). It should
be stressed that the inhibition of cell proliferation, as moni-
tored by BrdU LIs, clearly correlates with suppression of
ACF development by several chemopreventive agents (54,
55). In the present study, red ginseng reduced the BrdU
labeling index of crypt cells. Whether this is the only mech-
anism underlying red ginseng actions in our model, how-
ever, remains to be determined.
It is noteworthy in this context that red ginseng was effec-
tive for inhibition of ACF development during the initiation,
but not the promotion, phase. Reduction of ACF number
and multiplicity, as well as the relation of cancer chemopre-
vention in general to the initiation phase of carcinogenesis,
has been discussed in detail (14, 56). Belleli and others (57)
showed a 50% decrease in the number of colon tumors in rats
receiving 1, 25-(OH)2 vitamin D3 before carcinogen admin-
istration but found that the same treatment during the ini-
tiation or postinitiation phase did not change the tumor inci-
dence. Previously, Wattenberg (58) classified carcinogenesis
inhibitors according to the phase in which they show inhibito-
ry effects in animal models of carcinogenesis: 1) inhibitors
of the formation of the active carcinogen itself, 2) blocking
agents, which block the carcinogen at the initiation phase,
preventing it from reaching or reacting with target sites, and
3) suppressing agents, which suppress the formation of neo-
plasia when administered in the postinitiation phase. In our
model the formation of ACF was inhibited in rats receiving
red ginseng before carcinogen administration and in the ini-
tiation phase, suggesting that the agent might influence the
formation of active DMH itself and act as a blocking agent.
Metabolic studies are necessary to assess whether this is indeed
the case.
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